SINO BIOPHARM(01177) 华源证券·2025-03-26 10:31Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has achieved double-digit growth in both revenue and profit, with a focus on the global progress of its innovative pipeline [5][7] - The company reported a revenue of 28.87 billion RMB in 2024, representing a year-on-year growth of 10.2%, and an adjusted net profit of 3.46 billion RMB, up 33.5% year-on-year [7] - The revenue from innovative products reached 12.06 billion RMB in 2024, growing by 21.9%, accounting for 41.8% of total revenue [7] - The company has a rich pipeline of innovative products with high potential for international expansion [7] - The management has improved efficiency, leading to an increase in profit margins [7] Financial Forecasts and Valuation - The company expects to maintain double-digit growth in 2025, with projected revenues of 32.56 billion RMB and a net profit of 4.64 billion RMB, reflecting year-on-year growth rates of 12.8% and 32.6% respectively [6][7] - The earnings per share (EPS) is projected to be 0.25 RMB in 2025, with a price-to-earnings (P/E) ratio of 13.55 [6][7] - The company’s return on equity (ROE) is expected to be 12.7% in 2025 [6]